(function(){ var content_array=["
关于勃林格殷格翰<\/b> <\/p> \n
勃林格殷格翰是全球领先的生物制药企业,布局人用药品、动物保健两大业务领域。公司研发投入位居行业前列,致力于研究突破性疗法,解决巨大未满足的医疗需求,从而帮助改善或延长生命。自1885年成立以来,勃林格殷格翰一直是独立的家族企业,始终着眼长远发展,将可持续发展理念贯穿全价值链。公司在全球有超过5.35万名员工,服务逾130个市场,致力于打造一个更健康、更可持续、更公平的未来。更多详情,请访问:www.boehringer-ingelheim.cn<\/a>, www.boehringer-ingelheim.com<\/a><\/p> \n References<\/b> <\/p> \n [1] Richeldi L, et al. (2025) Nerandomilast in patients with idiopathic pulmonary fibrosis. In: NEJM. 2025.<\/span> <\/p> [2] Maher TM, et al. (2025) Nerandomilast in patients with progressive pulmonary fibrosis. In: NEJM. 2025.<\/span> <\/p> [3] Twisk JWR et al. (1998). Tracking of lung function parameters and the longitudinal relationship with lifestyle. European Respiratory Journal.<\/i> 12(3):627–634.<\/span> <\/p> [4] Sauleda J, et al. Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes. Med Sci (Basel). 2018 Nov 29;6(4):110. doi: 10.3390\/medsci6040110. PMID: 30501130; PMCID: PMC6313500.<\/span> <\/p> \n \n
\n